Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jazz Pharmaceuticals ( (JAZZ) ) has provided an announcement.
On July 24, 2025, Jazz Pharmaceuticals held its annual general meeting of shareholders in Dublin, Ireland, where four key proposals were voted on. The shareholders elected four directors to serve until 2028, ratified KPMG as independent auditors, approved executive compensation, and granted the board authority to issue shares without pre-emption rights, indicating strong shareholder support for the company’s strategic decisions.
The most recent analyst rating on (JAZZ) stock is a Buy with a $183.00 price target. To see the full list of analyst forecasts on Jazz Pharmaceuticals stock, see the JAZZ Stock Forecast page.
Spark’s Take on JAZZ Stock
According to Spark, TipRanks’ AI Analyst, JAZZ is a Outperform.
Jazz Pharmaceuticals exhibits a strong financial profile and strategic growth initiatives. Robust cash flow and neuroscience performance are key strengths, while moderate leverage and oncology challenges are risks.
To see Spark’s full report on JAZZ stock, click here.
More about Jazz Pharmaceuticals
Jazz Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing pharmaceutical products. The company is known for its work in the areas of sleep medicine and oncology, providing innovative treatments to address unmet medical needs.
Average Trading Volume: 924,373
Technical Sentiment Signal: Sell
Current Market Cap: $7.14B
See more insights into JAZZ stock on TipRanks’ Stock Analysis page.